Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

NCT04197986 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.

Conditions

Upper Tract Urothelial Carcinomas
Urothelial Bladder Cancer

Interventions

DRUG: Infigratinib
DRUG: Placebo

Sponsor

QED Therapeutics, a BridgeBio company

Collaborators

[object Object]